Our predicted HR-GES patient group had a much lower risk of EMR failure if treated with nilotinib upfront. (A) Bar plot demonstrates comparison of the EMR failure rate in patient samples assigned as high risk (HR-GES) by our predictive model if treated with imatinib (78%; n = 9) vs nilotinib upfront (10%; n = 20). (B) Bar plot demonstrates comparison of the EMR failure rate in patient samples assigned as low risk (LR-GES) by our predictive model if treated with imatinib (5%; n = 79) or nilotinib upfront (3%; n = 112). (C) Of the 132 patients treated with nilotinib upfront, there were 75 patients who had 24-month follow-up MR data. The high-risk patient group classified by our predictive model (n = 9) had inferior cumulative incidence of deep MR (MR4.5; >4.5 log reduction of BCR-ABL1 transcript value) by 24 months (0%) when compared with the low-risk patient group (29%; n = 66; P = .067). Statistical analysis was performed using the Fine and Gray test. (D) The high-risk patient group classified by our predictive model (n = 9) had no statistically significant difference in cumulative incidence of MMRs (>3 log reduction of BCR-ABL1 transcript value) by 24 months (78%) compared with the low-risk patient group (85%; n = 66; P = .55). Statistical analysis was performed using the Fine and Gray test.